GSK and XenoPort resubmit NDA for Solzira in restless legs syndrome

Editorial Checklist Reviewed
Jan 12 2009NewsGuard 100/100 Score

GlaxoSmithKline and XenoPort, Inc. announced today that GSK has resubmitted the New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) requesting approval of Solzira (gabapentin enacarbil) Extended Release Tablets for the treatment of moderate-to-severe primary Restless Legs Syndrome (RLS).

The FDA had requested that the data in a single study be reformatted. In addition, GSK conducted a review of other clinical studies taking this input into account. The withdrawal was not related to the content of the filing.

GlaxoSmithKline - one of the world's leading research-based pharmaceutical and healthcare companies - is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For further information please visit www.gsk.com.

Solzira - is a new chemical entity that is designed to improve upon the pharmacokinetics of gabapentin by taking advantage of high-capacity transport mechanisms in the gastrointestinal tract to improve absorption.

Source:

http://www.gsk.com/

Posted in: Pharmaceutical News

Tags: , , , , , , , , , ,

Comments (0)

Suggested Reading

Key triggers for food allergies in children after organ transplants
Not all ultra-processed foods are made alike: Researchers warn against villainizing entire food group
Frequent ultra-processed food consumption raises mortality risks, especially in women
Six common flying with food allergies myths
Ultra-processed food linked to weight gain and lower well-being in adolescents
Living in food deserts during early childhood raises long-term obesity risk
Limiting fast-food outlets can reduce childhood overweight and obesity
Updated Food Compass 2.0 improves food health ratings using new diet data

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback

You might also like...
Social media normalizes unhealthy food choices, shaping youth habits and brand loyalty